A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

• Status: Completed
• Trial end date: 2011-11-01

Summary

The Phase I portion of this protocol will determine the best phase II dose and schedule of obatoclax with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. The Phase II portion will evaluate the response rate to this regimen.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Gemin X
• Collaborator: Cephalon
• Treatments: Carboplatin; Etoposide; Etoposide phosphate; Obatoclax